MD

Today we will run through one way of estimating the intrinsic value of MEDNAX, Inc. (NYSE:MD) by projecting its future...

Shares of Mednax (NYSE:MD) rose 5.3% in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share fell 59.34% year over year to $0.37, which missed the estimate of $0.40.Revenue of $460,635,000 up by 1.26% year over year, which missed the estimate of $535,390,000.Guidance Mednax hasn't issued any earnings guidance for the time being.Mednax hasn't issued any revenue guidance for the time being.Conference Call Details Date: Nov 06, 2020View more earnings on MDTime: 09:00 AMET Webcast URL: https://edge.media-server.com/mmc/p/3c4h3xi9Technicals Company's 52-week high was at $28.66Company's 52-week low was at $7.37Price action over last quarter: down 25.93%Company Description Mednax provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment, which is physician services. Mednax generates roughly half of its revenue from the women's and children's services provided, and also roughly half of the company's total revenue is earned in the United States.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 6, 2020 * Earnings Outlook for Mednax(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Mednax (NYSE: MD) will be releasing its next round of earnings this Friday, November 06. For all of the relevant information, here is your guide for Friday's Q3 earnings announcement.Net Income, Earnings, And Earnings Per Share Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding.Earnings And Revenue Analysts covering Mednax modeled for quarterly EPS of $0.4 on revenue of $535.39 million. In the same quarter last year, Mednax reported EPS of $0.91 on revenue of $888.67 million.Why Analyst Estimates And Earnings Surprises Are Important Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin.View more earnings on MDIf the company were to match the consensus estimate when it reports Friday, EPS would have fallen 56.04%. Sales would be down 39.75% from the year-ago period. Here is how the company's reported EPS has compared to analyst estimates in the past:Quarter Q2 2020 Q1 2020 Q4 2020 Q3 2019 EPS Estimate 0.09 0.56 0.90 0.90 EPS Actual 0.32 0.32 0.91 0.91 Revenue Estimate 555.92 M 856.42 M 901.20 M 876.66 M Revenue Actual 509.20 M 845.92 M 905.38 M 888.67 M Stock Performance Over the past 52-week period, shares of Mednax have declined 46.91%.Do not be surprised to see the stock move on comments made during its conference call. Mednax is scheduled to hold the call at 09:00:00 ET and can be accessed here.See more from Benzinga * Click here for options trades from Benzinga * Atlantica Yield's Earnings: A Preview * CVS Health's Earnings Outlook(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MEDNAX 2020 Third Quarter Conference Call/Webcast Scheduled for Friday, November 6, 2020

Deutsche Bank analyst Pito Chickering downgrades Mednax (NYSE:MD) from Hold to Sell and lowers the price target from $20 to $12.

Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Imagine if you held MEDNAX, Inc...

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of June 30th, when the S&P 500 Index was trading around the […]